NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Tori Spelling, Patient Advocate

Advertisement

Articles by Tori Spelling, Patient Advocate

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

ByRenata Block, DMSc, MMS, PA-C,Adam Friedman, MD, FAAD,Tori Spelling, Patient Advocate,Stella McDermott, Patient Advocate,Maddi Hebebrand, MC, Associate Editor
December 4th 2025

Tori Spelling and Stella McDermott share their journey with eczema, promoting the Free to Be Me campaign and discussing innovative treatments like roflumilast.

Advertisement

Latest Updated Articles

  • Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
    Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

    Published: December 4th 2025 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

Kyowa Kirin Takes Full Control of Rocatinlimab Program

2

Dermatology Times January 2026 Recap

3

Phase 2 TYK2 Inhibition Shows Promise in AD

4

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

5

Galderma Prioritizes Menopause-Related Skin Health with New Data at IMCAS 2026

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us